New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System

MiniMed (Nasdaq: MMED) reported a randomized crossover trial showing virtually identical glycemic outcomes using the MiniMed 780G system with either Simplera Sync or Abbott’s Instinct sensor in 24 adults with type 1 diabetes.

Rhea-AI Summary

MiniMed (Nasdaq: MMED) reported a randomized crossover trial showing virtually identical glycemic outcomes using the MiniMed 780G system with either Simplera Sync or Abbott’s Instinct sensor in 24 adults with type 1 diabetes.

Time in Range was about 80%, HbA1c about 6.7–6.8%, with no DKA or severe hypoglycemia. Real-world data from over 20,000 U.S. users also showed strong glycemic control across Guardian 4 and Instinct sensors, supporting the central role of the SmartGuard algorithm.

Positive

• Randomized crossover trial (N=24) showed ~80% Time in Range with both sensors
• HbA1c around 6.7–6.8% across sensors using MiniMed 780G system
• No reported diabetic ketoacidosis, severe hypoglycemia, or unanticipated device effects
• Real-world data on 20,245 users showed 74.8–80.5% Time in Range
• High Time in Auto Mode up to 97.5% in real-world analysis

Negative

• None.

Argus May 21 session

+0.77% close to close Open Argus

Details

News Market Reaction – MMED

In the May 21 session, MMED gained 0.77%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlighted that the MiniMed 780G SmartGuard™ algorithm delivered virtually identi...

Analysis

This announcement highlighted that the MiniMed 780G SmartGuard™ algorithm delivered virtually identical glycemic outcomes across different sensors, with Time in Range around 80% and strong Auto Mode use. Real-world data on 20,245 users reinforced the algorithm’s central role. In context of prior milestones such as the IPO and FDA clearance of MiniMed Flex™, this adds evidence of clinical robustness, while investors may watch upcoming earnings and further usage data for additional confirmation.

Key Figures

Sample size (crossover trial): 24 participants Time in Range – Instinct: 79.1% Time in Range – Simplera Sync: 80.6% +5 more

Sample size (crossover trial)

24 participants

Randomized crossover MiniMed 780G with Simplera Sync vs Instinct sensors

Time in Range – Instinct

79.1%

70–180 mg/dL in randomized crossover trial

Time in Range – Simplera Sync

80.6%

70–180 mg/dL in randomized crossover trial

HbA1c – Instinct

6.7%

Randomized crossover trial with MiniMed 780G

HbA1c – Simplera Sync

6.8%

Randomized crossover trial with MiniMed 780G

Time in Auto Mode – Instinct

90.0%

Randomized crossover trial MiniMed 780G

Time in Auto Mode – Simplera Sync

92.6%

Randomized crossover trial MiniMed 780G

Real-world users analyzed

20,245 individuals

Real-world MiniMed 780G Guardian™ 4 vs Instinct sensor analysis

Historical Context

3 past events · Latest: Apr 13

3 events

1. Apr 13

   Earnings date set

   24h Move

   +5.7%

   Announced schedule for Q4 and full-year 2026 earnings release and webcast.

2. Mar 18

   FDA clearance pump

   24h Move

   -0.2%

   FDA cleared MiniMed Flex™, a smaller smartphone-controlled pump using SmartGuard™.

3. Mar 09

   IPO completion

   24h Move

   +1.8%

   Closed IPO of 28,000,000 shares at $20.00, raising ~$538M in net proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

automated insulin delivery, hbA1c, diabetic ketoacidosis, real-world evidence, +1 more

5 terms

automated insulin delivery medical

"reinforces SmartGuard™ algorithm as key driver of automated insulin delivery performance"

A system that links a glucose sensor, an insulin pump, and control software so insulin is adjusted automatically to keep blood sugar near a target range, similar to a smart thermostat that regulates room temperature. It matters to investors because it replaces manual dosing with continuous, data-driven care, which can drive device sales, recurring subscription software services, better health outcomes, and regulatory interest—factors that affect market growth and company valuation.

hbA1c medical

"HbA1c | 6.7 % | 6.8 %"

A1c (HbA1c) is a blood test that measures how much sugar has stuck to red blood cells over the past two to three months, giving a single number that reflects average blood glucose control—think of it as a running average score for blood sugar. Investors watch A1c because it’s a common clinical measure used to judge whether diabetes drugs, devices or care programs work, influence regulatory approvals, treatment guidelines and market demand.

diabetic ketoacidosis medical

"No cases of diabetic ketoacidosis (DKA), severe hypoglycemia, or unanticipated device effects"

Diabetic ketoacidosis is a serious, sudden complication of uncontrolled diabetes where the body, unable to use sugar for energy, breaks down fat and produces acidic chemicals called ketones, causing very high blood sugar, dehydration and a dangerous change in blood chemistry. It matters to investors because DKA drives hospital admissions, affects demand for diabetes medicines, devices and emergency care, and can influence clinical trial results, regulatory decisions and a company’s costs or liability exposure — like a sudden engine failure forcing expensive repairs.

real-world evidence medical

"Real-World Evidence Reinforces Clinical FindingsThese results build on preliminary real-world evidence"

Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.

algorithm technical

"the automated insulin delivery (AID) algorithm, not the sensor, is the primary determinant"

An algorithm is a step-by-step set of instructions a computer follows to solve a problem or make a decision, like a recipe that turns inputs into a specific output. Investors care because algorithms power automated trading, risk models, and data analysis that can speed decisions, amplify gains or losses, and affect market prices—so understanding their role helps assess how technology may influence a company's performance or market behavior.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Randomized crossover trial reinforces SmartGuard™ algorithm as key driver of automated insulin delivery performance

NORTHRIDGE, Calif., May 21, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced results from a new randomized crossover study demonstrating that glycemic outcomes for study participants were virtually identical when using the MiniMed™ 780G system with either the Simplera Sync™ sensor or Instinct sensor, made by Abbott. This data, published today in Diabetes Technology & Therapeutics, reinforces that the automated insulin delivery (AID) algorithm, not the sensor, is the primary determinant of clinical outcomes.¹

	Instinct (N=24)	Simplera Sync™ (N=24)
Time in Range     (70–180 mg/dL)	79.1 %	80.6 %
HbA1c	6.7 %	6.8 %
Mean Sensor Glucose	137.9 mg/dL	139.5 mg/dL
Time in Auto Mode	90.0 %	92.6 %

"These results underscore an important principle in automated insulin delivery, which is that the intelligence of the algorithm is what ultimately drives glycemic outcomes," said Principal Investigator Amir Tirosh, Director of the Division of Endocrinology, Diabetes, and Metabolism at Sheba Medical Center and Professor of Medicine at Tel Aviv University. "Across every key metric, the results between the two sensors were remarkably consistent, underscoring the strength and adaptability of the Minimed™ 780G system."

Twenty-four adult participants with type 1 diabetes were randomized to use either the Simplera Sync™ or Instinct sensor for a six-week period, then crossed over to the alternate sensor for an additional six weeks. Each crossover period utilized a new insulin pump to eliminate algorithm memory carryover effects.

Both sensors maintained strong Time in Range during the study period, exceeding international consensus targets for glycemic control as defined by the American Diabetes Association.² No cases of diabetic ketoacidosis (DKA), severe hypoglycemia, or unanticipated device effects were reported during the study.

Real-World Evidence Reinforces Clinical Findings
These results build on preliminary real-world evidence on 4,364 U.S. users of the MiniMed™ 780G system with type 1 diabetes that showed individuals who transitioned from the Guardian™ 4 sensor to the Instinct sensor maintained consistently strong glycemic outcomes. The data was presented at the International Conference on Advanced Technologies & Treatments for Diabetes in March by Viral N. Shah, MD, Professor of medicine in the division of endocrinology and metabolism and director of diabetes clinical research at Indiana University Center for Diabetes and Metabolic Diseases.^3,4

An updated real-world analysis of over 20,000 U.S. users of the MiniMed 780G system living with diabetes showed consistent results, validating the algorithm's central role in driving results.⁵

	Guardian™4 sensor Overall	Instinct sensor Overall	Guardian™ 4 sensor w/ Recommended Settings	Instinct sensor w/ Recommended Settings
Number of Individuals	20245	20245	8558	8558
Time in Range (70–180 mg/dL)	74.8 %	76.6 %	78.7 %	80.5 %
GMI	6.9 %	6.9 %	6.8 %	6.7 %
Time in Auto Mode	90.0 %	94.9 %	93.2 %	97.5 %

"This data provides compelling clinical validation of what we've always believed — that the power of our system lies in the intelligence of our SmartGuard™ algorithm," said Que Dallara, CEO of MiniMed. "This growing body of evidence gives people living with diabetes the confidence to choose a sensor from our portfolio that best fits their lifestyle. We're relentlessly focused on advancing the science behind automated insulin delivery and building a full-stack insulin delivery ecosystem that makes diabetes management simpler, more personalized, and increasingly hands-free."

About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's filings with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

¹ Laron-Hirsch, M., et al. Glycemic concordance of Simplera Sync™ and Instinct sensors in MiniMed™ 780G system users: A randomized crossover feasibility study. Diabetes Technology and Therapeutics. DOI:10.1177/15209156261449884
² American Diabetes Association Professional Practice Committee; 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025. Diabetes Care 1 January 2025; 48 (Supplement_1): S128–S145. https://doi.org/10.2337/dc25-S006
³ Medtronic data on file: MiniMed 780G data uploaded voluntarily by 4,364 eligible users to CareLink Personal, from 2 January 2020 to 31 January 2026
⁴ Shah VN, et al. Performance of a newly introduced sensor with an AID system: A real-world analysis. Presented at: International Conference on Advanced Technologies & Treatments for Diabetes; March 11-14, 2026; Barcelona, Spain.
⁵ Data on file.

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-study-showed-consistent-glycemic-outcomes-across-sensors-integrated-with-minimed-780g-system-302778917.html

SOURCE MiniMed

FAQ

What did MiniMed (Nasdaq: MMED) announce about MiniMed 780G glycemic outcomes on May 21, 2026?

MiniMed reported that MiniMed 780G delivered virtually identical glycemic outcomes with Simplera Sync and Instinct sensors. According to MiniMed, 24 adults with type 1 diabetes achieved about 80% Time in Range and HbA1c near 6.7–6.8%, with no severe safety events.

How did Simplera Sync and Instinct sensors compare in the MiniMed 780G randomized crossover trial?

The study found very similar glycemic metrics for Simplera Sync and Instinct with MiniMed 780G. According to MiniMed, Time in Range was 80.6% vs 79.1%, HbA1c 6.8% vs 6.7%, and Time in Auto Mode 92.6% vs 90.0%, respectively.

What were the key MiniMed 780G Time in Range and HbA1c results with MMED on May 21, 2026?

MiniMed 780G users in the study reached about 80% Time in Range and HbA1c around 6.7–6.8%. According to MiniMed, mean sensor glucose was roughly 138–140 mg/dL and Time in Auto Mode exceeded 90% for both sensors tested.

What real-world evidence did MiniMed share on Guardian 4 and Instinct sensors with MiniMed 780G?

MiniMed highlighted real-world data from over 20,000 U.S. MiniMed 780G users comparing Guardian 4 and Instinct sensors. According to MiniMed, Time in Range ranged from 74.8% to 80.5%, with Time in Auto Mode between 90.0% and 97.5% across groups.

Did the MiniMed 780G glycemic outcomes study report any safety concerns for MMED investors to note?

The study did not report major safety events such as diabetic ketoacidosis or severe hypoglycemia. According to MiniMed, there were also no unanticipated device effects during the crossover trial periods using Simplera Sync and Instinct sensors.

What does the MiniMed SmartGuard algorithm contribution mean for MMED’s automated insulin delivery strategy?

The results support SmartGuard as a main driver of MiniMed 780G clinical performance across different sensors. According to MiniMed, consistent outcomes in trials and real-world data suggest users can select sensors based on preference while relying on the algorithm’s control.